RxDoctor Payments Data

William Grubb, MD

Nephrology · Brunswick, GANPI 1093721532

Payments from drug & device makers

$11,328in general payments, 2019–2025

Across 555 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AstraZeneca$1K
  • Mallinckrodt Hospital Products Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$943
  • Travere Therapeutics, Inc.$726
  • OPKO Pharmaceuticals, LLC$714
  • plus $5K from 50 others

What the payments were for

  • Food & beverage$10,79995%
  • Education$5295%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)69$1,604
AstraZeneca(2 entities)66$1,175
Mallinckrodt Hospital Products Inc.48$1,035
Otsuka America Pharmaceutical, Inc.43$943
Travere Therapeutics, Inc.36$726
OPKO Pharmaceuticals, LLC37$714
Vifor Pharma, Inc.29$576
Ardelyx, Inc.10$487
Novartis17$410
Bayer21$345
Fresenius USA Marketing, Inc.16$311
Calliditas Therapeutics US Inc.12$211
Amarin Pharma, Inc.14$208
Mallinckrodt Enterprises LLC13$205
Akebia Therapeutics Inc11$173
AbbVie(2 entities)11$165
GSK6$137
Aurinia Pharma U.S., Inc.6$134
Corcept Therapeutics6$127
Insulet Corporation5$112
Shire North American Group Inc7$111
Takeda Pharmaceuticals U.S.A., Inc.5$99
Xeris Pharmaceuticals, Inc.4$93
Regeneron Healthcare Solutions, Inc.5$87
ANI Pharmaceuticals, Inc.3$81
Kowa Pharmaceuticals America, Inc.5$74
Kyowa Kirin, Inc.3$74
Boehringer Ingelheim3$72
Daiichi Sankyo Inc.3$63
Arbor Pharmaceuticals, Inc.4$63
Mannkind Corporation1$58
Novo Nordisk3$51
Lilly USA, LLC3$49
Pfizer3$46
E.r. Squibb & Sons, L.L.C.2$35
Astellas Pharma US Inc2$34
AMAG Pharmaceuticals, Inc.2$33
Apellis Pharmaceuticals, Inc.1$32
Esperion Therapeutics, Inc.2$31
Nxstage Medical, Inc.1$31
Ultragenyx Pharmaceutical Inc.2$29
Baxter Healthcare1$27
Alnylam Pharmaceuticals Inc.1$21
Ascendis Pharma Endocrinology Inc1$20
Sanofi1$20
Recordati_rare_diseases_inc.1$20
Exact Sciences1$19
Idorsia Pharmaceuticals US Inc1$19
Abbott1$18
Eyevance Pharmaceuticals LLC1$17
Hikma Pharmaceuticals USA1$17
Johnson & Johnson1$17
Nestle Healthcare Nutrition Inc.1$17
Aimmune Therapeutics, Inc.1$17
Portola Pharmaceuticals, LLC1$16
Paratek Pharmaceuticals, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,328 in reported general payments places this provider in the 80th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$230,855
Medicare patients
500
Services billed
2,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KrystexxaPegloticase12$710,711
FarxigaDapagliflozin Propanediol328$267,780
OzempicSemaglutide164$169,784
JardianceEmpagliflozin188$167,353
EliquisApixaban143$121,365
MounjaroTirzepatide38$37,583
ProliaDenosumab20$33,855
JanuviaSitagliptin Phosphate41$30,946
VascepaIcosapent Ethyl41$26,111
KerendiaFinerenone24$25,718
CreonLipase/Protease/Amylase25$24,662
XareltoRivaroxaban28$21,822
TradjentaLinagliptin20$18,898
Repatha SureclickEvolocumab27$18,859
Breo ElliptaFluticasone/Vilanterol31$13,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenKrystexxa, Prolia$1,604$744,56732 claims
AstraZenecaFarxiga, Symbicort$1,175$272,247348 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$72$198,975230 claims
Novo NordiskOzempic$51$169,784164 claims
PfizerEliquis$46$121,365143 claims
Lilly USA, LLCMounjaro, Humalog$49$40,54856 claims
BayerKerendia$345$25,71824 claims
AbbVieCreon$165$24,66225 claims
Johnson & JohnsonXarelto$17$21,82228 claims
GSKBreo Ellipta$137$13,21531 claims
Astellas Pharma US IncMyrbetriq$34$13,14224 claims
Arbor Pharmaceuticals, Inc.Edarbi$63$7,32214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 388 nephrology providers in Georgia.

Other nephrology in Brunswick

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →